A Pluripotent Road to Immunoengineering.
Where this comes from
- Record sourced from PubMed, PMID 41789189.
- Also identified by DOI 10.1038/s44222-023-00056-2 and PMC identifier 12959462.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Adoptive immunotherapy, particularly chimeric antigen receptor T cells, has achieved considerable success in treating hematologic malignancies over the past decade. However, variability, time commitment and high cost for engineering patient-derived cells have limited their application. Human pluripotent stem cells could provide an off-the-shelf, cheaper and scalable solution to these issues.